Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3071 Hormonal Ectopic Secretion Syndromes Associated to Neuroendocine Neoplasia
Introduction: Neuroendocrine neoplasias (NEN) are able to produce and secrete bioactive peptides and cause distinct syndromes related to their biological effects. The outcome will depend on the oncological disease as well as the hormonal syndrome
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Belli S
Authors: Belli S, Tkatch J, O'Connor J, Martinez M, Paissan A,
Keywords: ectopic secretion, hormonal syndrome, neuroendocrine neoplasia,
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,
Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Clift A
Authors: Clift A, Frilling A, Braat A, Alsafi A, Wasan H,
Keywords: liver, metastases, radioembolization, yttrium, selective internal radiation therapy,
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liu D
Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,
Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Refardt J
Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,
Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,